EFSD, Merck Sharp & Dohme (MSD): Novel Therapies for Type 2 Diabetes

Intended to fund preclinical/translational research on novel therapies to encourage the identification of new targets for the treatment of type 2 diabetes. Proposals may include but are not limited to:
- Mechanisms to induce “browning of adipose tissue”
- New targets for improving skeletal muscle or adipose tissue insulin resistance
- Bile acid biology as it relates to metabolic disease
- Lipid metabolism as it relates to insulin action
- Mechanisms of glucose-dependent insulin and glucagon secretion
Funding: up to €100,000, the duration of each award will depend upon the needs of the project.
http://www.europeandiabetesfoundation.org/index.php/ct-menu-item-5/14-sample-data-articles/233-msd-novel-therapies-for-type-2-diabetes-programme